GlyProVac
@glyprovac.com
Novel BEMAP TechnologyStarting with E. coli-based infections like UTIs, GlyProVac’s BEMAP platform is an engine for creating novel bacterial vaccines.
GlyProVac's Company Logos
GlyProVac's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FE2D2D
Red Orange
254, 45, 45
0, 99, 59
0, 82, 82, 0
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#111111
Cod Gray
17, 17, 17
0, 0, 7
0, 0, 0, 93
About GlyProVac
GlyProVac is a pioneering brand dedicated to developing glycoprotein-based vaccines. In response to the global challenge of antibiotic resistance (AMR), which is compromising our ability to treat infections, GlyProVac aims to provide safe and innovative solutions through vaccines. With the vision of reducing the projected 10 million annual deaths from untreatable microbial infections by 2050, GlyProVac is dedicated to designing and developing efficient bacterial vaccine candidates.
Leveraging their proprietary platform technology BEMAP, GlyProVac has made a paradigm-shifting discovery regarding sugar modifications in proteins of both benign and disease-causing bacteria like E. These modifications greatly impact protein topology and are specifically recognized by the human immune system. Building on this groundbreaking finding, GlyProVac believes that incorporating these modifications is crucial for the development of effective bacterial vaccines.
Currently, GlyProVac is focusing on establishing proof-of-concept for their novel bacterial vaccine concept within the E. For more details about their technology and endeavors, visit their website. Contact GlyProVac at their office address in Odense, Denmark, or through their email address
Company type
Privately Held
Year founded
2018
Company size
2-10 employees
